(Q36962239)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17919226%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

review article

1 reference

title

Treating nonalcoholic fatty liver disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17919226%20AND%20SRC:MED&resulttype=core&format=json

metabolic dysfunction–associated steatotic liver disease

8 January 2020

main subject

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17919226%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Misael Uribe

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17919226%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Nahum Méndez-Sánchez

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17919226%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Marco Arrese

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17919226%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

1 November 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17919226%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17919226%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17919226%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17919226%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

1157-1165

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17919226%20AND%20SRC:MED&resulttype=core&format=json

Current concepts in the pathogenesis of nonalcoholic fatty liver disease

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Review article: the metabolic syndrome and non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Nonalcoholic fatty liver disease and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Treatment of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Recent concepts in non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

The natural history of nonalcoholic fatty liver: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Role of liver biopsy in the assessment of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

AGA technical review on nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Hepatic decompensation after gastric bypass surgery for severe obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Hepatic effects of dietary weight loss in morbidly obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Pharmacologic management of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

An update on the pharmacological treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and bariatric surgery: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Hepatic histology in obese patients undergoing bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

NAFLD, obesity, and bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Treatment strategies in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Metformin in the treatment of patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Review article: Drug therapy for non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Pioglitazone in nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Review article: role of oxidative stress in the progression of non-alcoholic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Effect of ursodeoxycholic acid on hepatic steatosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Negative trials in nonalcoholic steatohepatitis: why they happen and what they teach us.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Increased orocecal transit time in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Probiotics: a potential target for the prevention and treatment of steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2007.01567.X